Questions About Cancer? 1-800-4-CANCER

Cancer Snapshots: Disease Focused and Other Snapshots

  • Posted: 12/02/2013

A Snapshot of Endometrial Cancer

Incidence and Mortality

Endometrial cancer is both the most common type of uterine cancer and the most common cancer of the female reproductive system, accounting for approximately six percent of all cancers in women in the United States. Since 2006, incidence rates have increased among all population groups. Overall mortality rates have increased slightly since the mid-1990s. Although the incidence rate of endometrial cancer is lower in African-American women than in whites, their mortality rate is nearly twice as high as that in all other racial/ethnic groups.

Several factors are associated with an increased risk of endometrial cancer, including obesity, exposure to endogenous or exogenous estrogens, tamoxifen use, and certain inherited conditions. Factors associated with a reduced risk include engaging in physical activity, taking combination oral contraceptives, and having a history of pregnancy and/or breastfeeding. Surgical removal of the uterus or hormone therapy is used to prevent endometrial cancer in women with endometrial hyperplasia. There is no standard or routine screening test for endometrial cancer. Standard treatments for endometrial cancer include surgery, radiation therapy, chemotherapy, and hormone therapy

It is estimated that approximately $2.6 billion1 is spent in the United States each year on uterine cancer treatment.

Line graphs showing U.S. Endometrial Cancer Incidence and mortality per 100,000 Women, by race and ethnicity, between 1990-2010. In 2010 whites have the highest incidence, followed by American Indians/Alaska natives, African Americans, Asians/Pacific Islanders, and Hispanics. In 2010, African Americans have the highest mortality followed by whites, American Indians/Alaska Natives, Hispanics, and Asians/Pacific Islanders.

Examples of NCI Activities Relevant to Endometrial Cancer

Selected Advances in Endometrial Cancer Research

Pie chart of NCI Endometrial Cancer Research Portfolio.  Percentage of total dollars by scientific area.  Fiscal year 2012.  Biology, 19%.  Etiology/causes of cancer, 9%.  Prevention, 9%.  Early detection, diagnosis, and prognosis, 37%.  Treatment, 15%.  Cancer control, survivorship, and outcomes research, 8%.  Scientific model systems, 3%.
  • In a study among Medicare beneficiaries, a laparoscopic hysterectomy for stage I endometrial cancer results in fewer complications than abdominal hysterectomy; however, uptake of this minimally invasive surgery has been slow. Published June 2012. [PubMed Abstract]
  • In an international study, women who last gave birth at age 40 or older had less than one-half the risk of endometrial cancer as women who last gave birth before age 25. Published July 2012. [PubMed Abstract]
  • The discovery of new genes that frequently are mutated in uterine serous carcinoma tumors points to potential new treatment targets for this aggressive form of endometrial cancer. Published January 2013. [PubMed Abstract]
  • DNA from endometrial cancers can be detected in a standard liquid Pap smear, a promising step toward a broadly applicable screen for early detection of this cancer. Published January 2013. [PubMed Abstract]
  • See this PubMed list of selected free full-text journal articles on NCI-supported research relevant to endometrial cancer. You can also search PubMed for additional scientific articles or to complete a search tutorial.

Trends in NCI Funding for Endometrial Cancer Research

The National Cancer Institute's (NCI) investment2 in endometrial cancer research increased from $17.1 million in fiscal year (FY) 2008 to $19.1 million in FY 2012. In addition to this funding, NCI supported $8.2 million in endometrial cancer research in FY 2009 and FY 2010 using funding from the American Recovery and Reinvestment Act (ARRA).

Bar graph of NCI Endometrial Cancer Research Investment in 2008-2012: Fiscal year (FY) 2008, $17.1 million Endometrial Cancer Funding of $4.83 billion Total NCI Budget. FY 2009, $18 million Endometrial Cancer Funding of $4.97 billion Total NCI Budget. FY 2010, $14.2 million Endometrial Cancer Funding of $5.10 billion Total NCI Budget. FY 2011, $15.9 million Endometrial Cancer Funding of $5.06 billion Total NCI Budget. FY 2012, $19.1 million Endometrial Cancer Funding of $5.07 billion Total NCI Budget.

Additional Resources for Endometrial Cancer

  • 1 Cancer Trends Progress Report, in 2010 dollars.
  • 2 The estimated NCI investment is based on funding associated with a broad range of peer-reviewed scientific activities. For additional information on research planning and budgeting at the National Institutes of Health (NIH), see About NIH.

Related Pages